Reig M et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681–693

Article  PubMed  Google Scholar 

Mazzaferro V et al (2013) Yttrium-90 radioembolization for intermediate–advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57:1826–1837

Article  CAS  PubMed  Google Scholar 

Sangro B, Carpanese L, Cianni R et al (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3):868–878

Article  PubMed  Google Scholar 

Salem R et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497-507.e2

Article  PubMed  Google Scholar 

Garin E et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6:17–29

Article  PubMed  Google Scholar 

Lam M et al (2022) A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging 49:3340–3352

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salem R et al (2021) Yttrium-90 radioembolization for the treatment of solitary. Unresectable HCC: The LEGACY Study 74:2021

Google Scholar 

Salem R et al (2019) Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 46:1695–1704

Article  PubMed  Google Scholar 

Kao YH et al (2013) Post-radioembolization yttrium-90 PET/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res 3:1–27

Google Scholar 

Child C, Turcotte J (1964) Surgery and portal hypertension. Major Probl Clin Surg 1:1–85

CAS  PubMed  Google Scholar 

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022

Article  PubMed  Google Scholar 

Durand F, Valla D (2008) Assessment of prognosis of cirrhosis. Semin Liver Dis 28:110–122

Article  CAS  PubMed  Google Scholar 

Johnson P et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558

Article  PubMed  Google Scholar 

Navadurong H et al (2023) Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis. World J Gastroenterol 29:4873–4882

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reincke M et al (2022) Hepatic decompensation after transarterial radioembolization: a retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun 6:3223–3233

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lescure C et al (2021) Albi score is a strong predictor of toxicity following sirt for hepatocellular carcinoma. Cancers 13(15):3794. https://doi.org/10.3390/cancers13153794

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evirgen S et al (2023) Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin–bilirubin score’s prediction factor for survival? Hepatology Forum 4:103–107

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohammadi H et al (2018) Using the albumin–bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol 9:840–846

Article  PubMed  PubMed Central  Google Scholar 

Antkowiak M et al (2019) Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers 11(6):879. https://doi.org/10.3390/cancers11060879

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber M et al (2022) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 49:1682–1699

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fisher L, Lin D (1999) Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20:145–157

Article  CAS  PubMed  Google Scholar 

Pinato DJ et al (2017) The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 66:338–346

Article  PubMed  Google Scholar 

Hickey R et al (2016) Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol 27:795–802

Article  PubMed  Google Scholar 

Gui B et al (2018) Assessment of the albumin–bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. American J Clin Oncol: Cancer Clin Trials 41:861–866

Article  CAS  Google Scholar 

Salem R et al (2021) Yttrium-90 radioembolization for the treatment of solitary. Unresectable HCC: The LEGACY Study Hepatol 74:2342–2352

CAS  Google Scholar 

Vouche M et al (2013) Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 59:1029–1036

Article  PubMed  PubMed Central  Google Scholar 

Demirtas CO, D’Alessio A, Rimassa L, Sharma R, Pinato DJ (2021) ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Reports 3(5):100347. https://doi.org/10.1016/j.jhepr.2021.100347

Article  PubMed  PubMed Central  Google Scholar 

Chow PKH et al (2018) SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 36:1913–1921

Article  CAS  PubMed  Google Scholar 

Gallio E et al (2016) Calculation of tumour and normal tissue biological effective dose in 90Y liver radioembolization with different dosimetric methods. Physica Med 32:1738–1744

Article  Google Scholar 

Cerreto M et al (2023) The new era of systemic treatment for hepatocellular carcinoma: from the first line to the optimal sequence. Curr Oncol 30(10):8774–8792

Article  PubMed  PubMed Central  Google Scholar 

Villalobos A et al (2023) Safety and efficacy of concurrent atezolizumab/bevacizumab or nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. Curr Oncol 30(12):10100–10110

Article  PubMed  PubMed Central  Google Scholar 

Yeo YH et al (2023) Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma. Am J Gastroenterol 118(12):2201–2211

Article  CAS  PubMed  Google Scholar